Business
Satellos Bioscience Announces Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Sate...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Announces Grant of Stock OptionsToronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (\"Satellos\" or the \"Company\"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that its board of directors (the \"Board\") has approved grants of stock options (the \"Stock Options\") pursuant to the terms of the Company's Stock Option Plan. A total of 5,732,797 Stock Options have been awarded to directors, officers, employees and consultants of the Company. The Stock Options are exercisable at a price of $0.60 per share for a period of 10 years from the date of the grant. About Satellos Bioscience Inc.Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body's innate muscle repair and regeneration process. The Company's lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit Satellos.com.CONTACT:Business DevelopmentRyan Mitchell, [email protected] at Satellos Bioscience Inc.Christina [email protected]+1.647.660.1780For MediaJessica Yingling, [email protected]+1.858.344.8091Notice on forward-looking statements:This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future perform...